September 10, 2007 – Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that its Monte Carlo Dose Calculation algorithm has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available worldwide. This announcement was made as part of the product’s launch at the 9th Biennial European Society for Therapeutic Radiology and Oncology (ESTRO) meeting on Physics and Radiation Technology for Clinical Radiotherapy in Barcelona, Spain..."The clearance and commercial availability of Accuray's Monte Carlo Dose Calculation algorithm is a significant milestone in the use of radiosurgery to treat tumors anywhere in the body, particularly lung tumors" said Euan S. Thomson, Ph.D., president and CEO of Accuray... Accuray's Press Release -
Sep 11, 2007
Accuray, FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
September 10, 2007 – Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that its Monte Carlo Dose Calculation algorithm has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available worldwide. This announcement was made as part of the product’s launch at the 9th Biennial European Society for Therapeutic Radiology and Oncology (ESTRO) meeting on Physics and Radiation Technology for Clinical Radiotherapy in Barcelona, Spain..."The clearance and commercial availability of Accuray's Monte Carlo Dose Calculation algorithm is a significant milestone in the use of radiosurgery to treat tumors anywhere in the body, particularly lung tumors" said Euan S. Thomson, Ph.D., president and CEO of Accuray... Accuray's Press Release -
